公开(公告)号：US20180251488A1

公开(公告)日：2018-09-06

申请号：US15760513

申请日：2016-09-20

申请人： MITSUBISHI TANABE PHARMA CORPORATION ,  OSAKA UNIVERSITY

发明人： Satoshi OBIKA ,  Eiji KAWANISHI ,  Hiroaki SAWAMOTO ,  Shuhei YAMAKOSHI ,  Yuuki ARAI ,  Shinji KUMAGAI

IPC分类号： C07H19/06 ,  C07H9/06

CPC分类号： C07H19/06 ,  C07C279/16 ,  C07D498/04 ,  C07D498/08 ,  C07H1/00 ,  C07H9/06 ,  C07H19/16 ,  C07H21/00

摘要： The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides a method for producing a compound represented by general formula I: (in the formula, R1, R2, R3, R4, R5, R6, m and ring A are as defined in the specification) or a salt thereof wherein a reducing agent is reacted with a compound represented by general formula II: (in the formula, R1, R2, R3, R4, R5, R6, m, and ring A′ are as defined in the specification).

公开(公告)号：US20180282363A1

公开(公告)日：2018-10-04

申请号：US16000079

申请日：2018-06-05

申请人： MITSUBISHI TANABE PHARMA CORPORATION

发明人： Sumihiro NOMURA ,  Eiji KAWANISHI ,  Kiichiro UETA

IPC分类号： C07H19/056 ,  C07H19/048 ,  C07H19/044 ,  C07H19/04 ,  C07H7/06 ,  A61K31/7056 ,  A61K38/24 ,  A61K38/28 ,  A61K45/06 ,  A61K31/7042 ,  C07H7/04

摘要： A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

公开(公告)号：US20160108078A1

公开(公告)日：2016-04-21

申请号：US14981728

申请日：2015-12-28

申请人： MITSUBISHI TANABE PHARMA CORPORATION

发明人： Sumihiro NOMURA ,  Eiji KAWANISHI ,  Kiichiro UETA

IPC分类号： C07H19/056 ,  C07H19/044 ,  C07H19/04 ,  C07H19/048 ,  C07H7/04 ,  C07H7/06

CPC分类号： C07H19/056 ,  A61K31/7042 ,  A61K31/7056 ,  A61K38/24 ,  A61K38/28 ,  A61K45/06 ,  C07H7/04 ,  C07H7/06 ,  C07H19/04 ,  C07H19/044 ,  C07H19/048 ,  A61K2300/00

摘要： A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

摘要翻译： 下式的化合物：其中环A和环B是：（1）环A是任选取代的不饱和单环杂环，环B是任选取代的不饱和单环杂环，任选取代的不饱和稠合杂双环，或 任选取代的苯环，（2）环A是任选取代的苯环，环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环，或（3）环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环，任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y为 - （CH 2）n - （n为1或2）; 或其药学上可接受的盐，或其前药。

公开(公告)号：US20140296506A1

公开(公告)日：2014-10-02

申请号：US14299470

申请日：2014-06-09

申请人： MITSUBISHI TANABE PHARMA CORPORATION

发明人： Sumihiro NOMURA ,  Eiji KAWANISHI ,  Kiichiro UETA

IPC分类号： C07H7/04

CPC分类号： C07H19/056 ,  A61K31/7042 ,  A61K31/7056 ,  A61K38/24 ,  A61K38/28 ,  A61K45/06 ,  C07H7/04 ,  C07H7/06 ,  C07H19/04 ,  C07H19/044 ,  C07H19/048 ,  A61K2300/00

摘要： A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

摘要翻译： 下式的化合物：其中环A和环B是：（1）环A是任选取代的不饱和单环杂环，环B是任选取代的不饱和单环杂环，任选取代的不饱和稠合杂双环，或 任选取代的苯环，（2）环A是任选取代的苯环，环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环，或（3）环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环，任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y为 - （CH 2）n - （n为1或2）; 或其药学上可接受的盐，或其前药。